1
Apr
2019
IFM Nails Second Big Deal, Selling NLRP3 Inhibitors to Novartis for $310M Upfront
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
28
Mar
2019
Thermo Bets on Viral Vector Manufacturing, Precision & Genfit’s IPOs, & Not Much Else
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
26
Mar
2019
Life of a Scientific Entrepreneur: Bob Langer of MIT on The Long Run
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
22
Mar
2019
Sage’s Depression Triumph, Biogen’s Alzheimer’s Defeat, & Apple Watch Hype
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
14
Mar
2019
Sharpless in the Saddle, NIH Threatened Again, & PBMs Prep for Senate Scrutiny
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
12
Mar
2019
Seeing Lots of Single Cells, Up Close: Serge Saxonov of 10X Genomics on The Long Run
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
7
Mar
2019
Gottlieb Exits, Biogen’s Big Gene Therapy Buy, and Lilly’s Pre-Emptive Price Cut
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Mar
2019
Beam Therapeutics, Pushing The Edges in Base Editing, Raises $135M
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
1
Mar
2019
Pharma Dodges Senate Bullet, Roche Pays $4.8B for Spark, & BMS-Celgene Deal Wobbles
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
28
Feb
2019
Third Rock, Arch Join at Hip, Lead $191M Bet on Maze and ‘Gene Modifiers’
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
27
Feb
2019
Staying Resilient, Finding a Way Forward: Julia Owens on The Long Run
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Feb
2019
The Boston Cancer Summit and SF Cancer Summit. See the Agenda & Get Your Tickets
The Boston Cancer Summit is loaded with a stellar lineup of speakers on Apr. 16. Same deal with the San Francisco Cancer Summit on Apr. 18. I’m excited to announce the agendas for these special idea-and-networking forums. Hal Barron of GSK, David Schenkein of GV, Cindy Perettie of Foundation Medicine, and Ira Mellman of Genentech are a few of the... Read More
15
Feb
2019
The PCSK9 Price Cut, J&J Depression Drug Passes Test, & Gilead’s NASH Strikeout
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
12
Feb
2019
The Immune Sequencing Frontier (Take 2): Harlan and Chad Robins on The Long Run
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Feb
2019
Azar Angles for a Deal Pharma Can Live With, Macrogenics’ Big Break, & Sanofi Scraps 38 R&D Programs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
7
Feb
2019
Meet the Kilimanjaro Climb to Fight Cancer Team
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Feb
2019
Get Tickets Now: The Cancer Summit Series is Coming to Boston, SF, Seattle
We live in a time of tremendous possibility for cancer R&D. Checkpoint inhibitors, cell therapies, molecular diagnostics that catch cancer early and can guide effective custom treatment – these fields are brimming with progress. All were considered speculative at best a decade ago. The science has never been more promising. Yet pricing and access to this new world of cancer... Read More
30
Jan
2019
Finding a Way in Genomic Diagnostics: Bonnie Anderson of Veracyte on The Long Run
Bonnie Anderson is today’s guest on The Long Run. Bonnie is the CEO of Veracyte. It’s a genomic diagnostics company in South San Francisco. The company markets a line of tests for thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. Veracyte got started in 2008. Bonnie, as co-founder and CEO, was recruited by Kleiner Perkins Caufield & Byers and a... Read More
25
Jan
2019
Genentech CEO in, Editas CEO Out, & the Shutdown IPO?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
18
Jan
2019
House Dems Hunt Pharma Big Game, Shutdown Ripples, & JPM Reflections
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.